EUCTR2006-001834-42-IT进行中（未招募）不适用
A Multi-Center, Open label, Repeated Dose Range Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Efficacy of an Anti-IL-1 946; Monoclonal Antibody ACZ885 Given Subcutaneously in Pediatric Subjects with Active Systemic Juvenile Idiopathic Arthritis SJIA - CACZ885A2203
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •male female subjects aged 4 to 20 having passed screening exams female child bearing potential with negative pregnancy test at screening and willing to use contraception for three months afetr the end of treatment
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •use of etanercept in the four weeks prior to the baseline visit adalimumab in the eight weeks prior to the baseline visit infliximab in the 8 w prior to baseline visit
研究者
相似试验
进行中（未招募）
1 期
A Multi-Center, Open label, Repeated Dose Range Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Efficacy of an Anti-IL-1ß Monoclonal Antibody (ACZ885) Given Subcutaneously in Pediatric Subjects with Active Systemic Juvenile Idiopathic Arthritis (SJIA) - CACZ885A2203Systemic Juvenile Idiopathic Arthritis (SJIA)MedDRA version: 8.1 Level: PT Classification code 10059177 Term: Juvenile arthritisEUCTR2006-001834-42-GBovartis Pharma Services AG26
已完成
2 期
A Multi-Center, Open label, Repeated Dose Range Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Efficacy of an Anti-IL-1β Monoclonal Antibody (ACZ885) Given Subcutaneously in Pediatric Subjects with Active Systemic Juvenile Idiopathic Arthritis (SJIA)Joint inflammation with childrenSystemic Juvenile Idiopathic Arthritis (SJIA)10010761NL-OMON30805ovartis6
进行中（未招募）
不适用
A Multi-Center, Open label, Repeated Dose Range Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Efficacy of an Anti-IL-1ß Monoclonal Antibody (ACZ885) Given Subcutaneously in Pediatric Subjects with Active Systemic Juvenile Idiopathic Arthritis (SJIA)Systemic Juvenile Idiopathic Arthritis (SJIA)MedDRA version: 8.1Level: PTClassification code 10059177Term: Juvenile arthritisEUCTR2006-001834-42-FRovartis Pharma Services AG26
进行中（未招募）
不适用
A Multi-center, open-label, multiple dose, dose finding study exploring the safety and tolerability of Beraprost Sodium Modified Release in PAH patientsPulmonary Arterial HypertensionMedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionEUCTR2008-003290-41-IEungRx10
进行中（未招募）
不适用
A Multi-center, open-label, multiple dose, dose finding study exploring the safety and tolerability of Beraprost Sodium Modified Release in PAH patientsMedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionPulmonary Arterial HypertensionEUCTR2008-003290-41-BEung Rx20